CAR T-Cell Therapy for Non-Hodgkin Lymphoma: An Overview

CAR T-cell therapy is a form of immunotherapy that uses a patient's own immune cells to fight cancer. T cells are a type of white blood cell that normally patrols the body for threats, but lymphoma cells can hide from them. In CAR T-cell therapy, T cells are collected from the patient, genetically engineered in a laboratory to carry a chimeric antigen receptor — a synthetic protein that locks onto a marker found on lymphoma cells, most often CD19 — and then returned to the patient as a living, one-time infusion. Once inside the body, the modified cells multiply, seek out cells carrying that marker, and destroy them.

For people with relapsed or refractory non-Hodgkin lymphoma — disease that has come back after treatment or never fully responded to it — CAR T-cell therapy can offer durable remission where additional lines of chemotherapy may not. Several CAR T-cell products are approved by the U.S. Food and Drug Administration for large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, and each has its own approved indication and prior-therapy requirements. Because the therapy is manufactured individually for each patient and requires specialized monitoring, it is delivered only at authorized treatment centers, which means most patients begin the process with a referral from their community oncologist.

The therapy also carries distinctive risks. Cytokine release syndrome, an inflammatory reaction that can cause fever, low blood pressure, and difficulty breathing, and neurologic effects such as confusion, tremor, or difficulty speaking are both recognized in FDA boxed warnings. These reactions usually appear within the first days to weeks after infusion and are managed with established protocols, which is why patients are monitored intensively and asked to remain close to the treatment center during that window. Prolonged low blood counts and increased infection risk can persist longer and are followed over time.

Understanding the sequence of steps ahead of time makes the process far less overwhelming. Below is the typical path from referral through long-term follow-up.